Clinical trials: aldesleukin
Systemic Lupus Erythematosus
The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic Diseases
The study aims to explore the therapeutic value and mechanism of Interleukin-2 on children with rheumatic diseases (Systemic Lupus Erythematosus, Primary Sjögren Syndrome, Juvenile Idiopathic Arthritis).
- Trial name
- SLE，pSS，JIA (NCT04397107)
- Testing
- IL-2
- Where
- China
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- The First Hospital of Jilin University
Covid19
Survival TRial Using CytoKines in COVID-19 (STRUCK Trial)
Currently, there are few approved treatments for COVID-19, antiretroviral (remdesivir) and corticoids. With about 15% of COVID-19 patients suffering from severe disease health system will be overwhelmed.
- Trial name
- STRUCK (NCT04724629)
- Testing
- Ixekizumab, Aldesleukin, Colchicine
- Where
- 2 sites in Brazil
- Volunteers
- 60 people
- Sponsor
- University of Sao Paulo
Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia
Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant
This phase I/II trial studies the side effects of laboratory-treated T cells and to see how well they work in treating patients with high-risk acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelogenous…
- Conditions
- Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
- Trial name
- NCT01640301
- Testing
- Aldesleukin, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Fred Hutchinson Cancer Center
Cervical Cancer, Renal Cancer
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with metastatic cancer that involves taking white blood cells from the patient, growing them in the…
- Conditions
- Cervical Cancer, Renal Cancer, Urothelial Cancer, Melanoma
- Trial name
- NCT02111850
- Testing
- Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL), Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Primary Mediastinal B-cell Lymphoma, Diffuse, Large B-cell Lymphoma
CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with B cell lymphomas or leukemias that involves taking white blood cells from the patient, growing them…
- Conditions
- Primary Mediastinal B-cell Lymphoma, Diffuse, Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma, Mantle Cell
- Trial name
- NCT00924326
- Testing
- Fludarabine, Cyclophosphamide, Anti-cluster of differentiation 19 (CD19)-CAR PBL
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma
Study of Gene Modified Immune Cells in Patients With Advanced Melanoma
The purpose of this phase 2 study is to find the best way to give this new experimental regimen and determine if it can treat metastatic melanoma in humans.
- Trial name
- F5 (NCT00910650)
- Testing
- F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells, non-myeloablative conditioning chemotherapy
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Jonsson Comprehensive Cancer Center
HIV Infections
An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy
The purpose of this study is to see if it is effective to give HIV positive patients recombinant interleukin-2 (rIL-2) in addition to anti-HIV therapy.
- Trial name
- ESPRIT (NCT00004978)
- Testing
- Recombinant interleukin-2 (rIL-2)
- Where
- 248 sites in United States, Argentina and 23 more
- Volunteers
- 4,150 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
The Safety and Effectiveness of Interleukin-2 Plus Zidovudine in Patients With AIDS or AIDS Related Complex
To test the safety and tolerance of three different doses of recombinant human interleukin 2 (aldesleukin; IL-2), when it is given for five consecutive days to patients with AIDS or AIDS related complex (ARC), who have also…
- Trial name
- NCT00000986
- Testing
- Zidovudine, Aldesleukin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes
AMENDED: To investigate whether subcutaneous (SC) injection of IL-2 produces biological responses which parallel those observed with IV dosing.
- Trial name
- NCT00001005
- Testing
- Zidovudine, Aldesleukin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People
The purpose of this study is to determine the effect of short cycles of recombinant interleukin-2 (also known as rIL-2 or aldesleukin) given with or without anti-HIV drugs in HIV infected patients.
- Trial name
- STALWART (NCT00110812)
- Testing
- IL-2
- Where
- 36 sites in United States, Argentina and 9 more
- Volunteers
- 267 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Phase I Trial of the Combination of Zidovudine and Recombinant Interleukin-2 in Patients With Persistent Generalized Lymphadenopathy
To evaluate the short-term effects of administering zidovudine ( AZT ) at the same time with increasing doses of aldesleukin ( interleukin-2; IL-2 ) in patients with persistent generalized lymphadenopathy syndrome ( PGL ).
- Trial name
- NCT00000728
- Testing
- Zidovudine, Aldesleukin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Subcutaneously Administered Aldesleukin ( Interleukin-2; IL-2 ) Therapy in HIV-Infected Patients
To compare the effects of low-dose versus high-dose subcutaneous ( SC ) aldesleukin ( interleukin-2; IL-2 ) on immunologic and virologic markers in HIV-infected patients.
- Trial name
- NCT00000821
- Testing
- Aldesleukin
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Phase I Study of Autologous, Activated CD8(+) Lymphocytes Expanded In Vitro and Infused With or Without Recombinant Interleukin-2 to Patients With AIDS or Severe ARC
1) To determine whether it is possible to remove and culture (increase in number and activate) in the laboratory, CD8(+) lymphocytes (white blood cells) from HIV-infected patients receiving zidovudine (AZT); 2) To determine the…
- Trial name
- NCT00000680
- Testing
- Zidovudine, Aldesleukin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems
The purpose of this study is to determine the safety of a drug called interleukin-2 (IL-2) given with anti-HIV therapy in children with HIV infection. This study will also determine the best dose of IL-2 to give children.
- Trial name
- NCT00006066
- Testing
- Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Diphtheria and Tetanus Toxoids Adsorbed, Tetanus and Diphtheria Toxoids Adsorbed
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 92 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination
The purpose of this study is to see if adding an HIV vaccine (ALVAC-HIV vCP1452), IL-2 (interleukin-2, a protein found in the blood that helps boost the immune system), or both to anti-HIV-drug therapy is safe, tolerable, and…
- Trial name
- NCT00006291
- Testing
- ALVAC(2)120(B,MN)GNP (vCP1452), Aldesleukin
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Hepatitis C
Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection
This study will test the safety and effectiveness of a new treatment for hepatitis C (HCV) in patients who also have HIV. The usual treatment for HCV in people who are not HIV-infected is interferon-alfa (IFN) with ribavirin…
- Trial name
- NCT00015652
- Testing
- Ribavirin, Aldesleukin, Peginterferon alfa-2b
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Effect of Interleukin-2 on HIV Treatment Interruption
Interleukin-2 (IL-2) helps the body make infection-fighting white blood cells, including CD4 and CD8 T cells. One HIV treatment strategy is planned treatment interruption (stopping anti-HIV drugs when CD4 count and level of virus…
- Trial name
- NCT00015704
- Testing
- Aldesleukin
- Where
- 17 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Interleukin-2 (IL-2) Treatment for HIV Infected Patients Who Have Interrupted Their Anti-HIV Drug Therapy
When an HIV infected person taking strong anti-HIV drugs temporarily stops taking them, viral load rises and the body's immune system is exposed to more HIV.
- Trial name
- NCT00038259
- Testing
- Aldesleukin
- Where
- 10 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3
The purpose of this study is to evaluate the safety and tolerability of giving IL-2 plus anti-HIV (antiretroviral) therapy to HIV-positive patients with CD4 cell counts (cells of the immune system that fight infection) of at…
- Trial name
- NCT00000825
- Testing
- Aldesleukin
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study to Test the Safety of Recombinant Interleukin-2 (rIL-2) in HIV-Infected Children
The purpose of this study is to determine the safety and maximum tolerated dose (the highest dose that can be given safely) of recombinant Interleukin-2 (rIL-2) in HIV-infected children.
- Trial name
- NCT00000849
- Testing
- Aldesleukin
- Where
- 14 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)